Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.62 |
| ▸ | RET | P07949 | 3/20 | 0.59 |
| ▸ | MET | P08581 | 8/20 | 0.58 |
| ▸ | AXL | P30530 | 4/20 | 0.58 |
| ▸ | KIT | P10721 | 3/20 | 0.58 |
| ▸ | FLT3 | P36888 | 3/20 | 0.58 |
| ▸ | PLK4 | O00444 | 2/20 | 0.58 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.58 |
| ▸ | STK10 | O94804 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | FYN | P06241 | 2/20 | 0.58 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | YES1 | P07947 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veonetinib SCHEMBL31515076 | 0.96 | KDR (0.63) | KDRPDGFRBRETMETAXL | |
| Veonetinib SCHEMBL30631724 | 0.96 | KDR (0.63) | KDRPDGFRBRETMETAXL | |
| Veonetinib SCHEMBL26938478 | 0.96 | KDR (0.63) | KDRPDGFRBRETMETAXL | |
| Veonetinib SCHEMBL31515075 | 0.96 | KDR (0.63) | KDRPDGFRBRETMETAXL | |
| Veonetinib SCHEMBL239435 | 0.96 | KDR (0.63) | KDRPDGFRBRETMETAXL | |
| Veonetinib SCHEMBL26938477 | 0.96 | KDR (0.63) | KDRPDGFRBRETMETAXL | |
| SCHEMBL242187 | 0.92 | KDR (0.63) | KDRPDGFRBRETMETAXL | |
| SCHEMBL244278 | 0.88 | KDR (0.64) | KDRPDGFRBRETMETAXL | |
| SCHEMBL242803 | 0.85 | KDR (0.63) | KDRPDGFRBRETMETAXL | |
| SCHEMBL242594 | 0.84 | KDR (0.65) | KDRPDGFRBRETMETAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312950-B1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LAB LLC (US) | 2016-11-30 | — | — | EP | claimed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | claimed |
| JP-2012500269-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2312950-A1 | COMPOUNDS AS KINASE INHIBITORS | Advenchen Laboratories, LLC (US) | 2011-04-27 | — | — | EP | claimed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | claimed |
| WO-2010021918-A1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2010-02-25 | — | — | WO | claimed |
| EP-2312950-B1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LAB LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2312950-B1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LAB LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211911-B2 | Compounds as kinase inhibitors | CHEN GUOQING PAUL (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2312950-A1 | COMPOUNDS AS KINASE INHIBITORS | Advenchen Laboratories, LLC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
| US-20100048599-A1 | Compounds As Kinase Inhibitors | CHEN GUOQING PAUL | 2010-02-25 | — | — | US | disclosed |
| WO-2010021918-A1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021918-A1 | COMPOUNDS AS KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048599-A1 | Compounds As Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K6 | KDR 44/4885PDGFRB 148/4885RET 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.